Health Care & Life Sciences » Biotechnology | Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
60.56 M
Public Float
31.46 M
Karyopharm Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$3.44
Market Cap
$536.21 M
Shares Outstanding
60.86 M
Public Float
53.35 M

Profile

Address
85 Wells Avenue
Newton Massachusetts 02459
United States
Employees -
Website http://www.karyopharm.com
Updated 07/08/2019
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, The engages in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A.

Financials

View All
Created with Highcharts 5.0.14Karyopharm Therapeutics Inc.Net Income. Fiscal year is January-December. All values USD Thousands.33 94733 94775 77775 777118 181118 181109 577109 577128 984128 984178 407178 407201320142015201620172018050k100k150k200k
Created with Highcharts 5.0.14Karyopharm Therapeutics Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.3873872292292502501541541 6051 60530 33630 336201320142015201620172018010k20k30k40k

Mansoor Raza Mirza
Independent Director
Michael F. Falvey
Chief Financial Officer, Treasurer & Executive VP